Keywords: genentech, beats, forecasts, oncology, franchise, drives, strong
Genentech beats forecasts, as oncology franchise drives strong 3rd quarter
Article | 13 October 2003
The world's oldest biotechnology concern, Genentech, has reported a strong performance for third-quarter 2003 on the back of its two top-selling ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
